Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Conclusion: This real-world study demonstrated a significant economic burden in mCSPC patients, and a propensity to use ADT monotherapy in clinical practice despite the availability and guideline recommendations of advanced life-prolonging therapies.PMID:38420699 | DOI:10.1080/13696998.2024.2323901
Source: Journal of Medical Economics - Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Patrick Lefebvre Dominic Pilon Daniel George Source Type: research
More News: Cancer | Cancer & Oncology | Economics | Health Management | Immunotherapy | Insurance | Prostate Cancer | Statistics | Study | USA Health